RecruitingNCT05025878

13C-Glucose Tracing of Tumour and T Cells in the Ascites of Ovarian Cancer Patients.

Metabolic Tracing of Tumour and T Cells in the Ascites of Ovarian Cancer Patients


Sponsor

British Columbia Cancer Agency

Enrollment

10 participants

Start Date

Oct 20, 2021

Study Type

OBSERVATIONAL

Conditions

Summary

The objective of the study is to investigate the metabolism of cells in the ascites tumour microenvironment of ovarian cancer patients. This observational study involves intravenous infusion of \[U-13C\]glucose into patients during standard paracentesis.


Eligibility

Sex: FEMALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study explores how cancer cells and immune cells use sugar (glucose) for energy in the fluid that builds up in the abdomen (called ascites) of ovarian cancer patients. Researchers give a specially labeled glucose through an IV and then analyze the collected fluid to better understand tumor metabolism — which could lead to new treatments. **You may be eligible if...** - You have ovarian cancer at any stage - You have fluid buildup in your abdomen that needs to be drained - You are able to understand the study and give your consent **You may NOT be eligible if...** - You have diabetes or abnormal blood sugar control (abnormal HbA1c) - Your blood glucose is outside the normal range on the day of the infusion - You are receiving chemotherapy during the 5-hour study period Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENT[U-13C]Glucose

Patients are intravenously infused with 28g of \[U-13C\]glucose over a 5 hour period. Briefly, \[U-13C\]glucose will be provided by intravenous line containing 8g of \[U-13C\]glucose in 60 mL over 10 min. After 10 minutes, 4g of \[U-13C\]glucose will be administered over an hour. This process will continue until the patient's ascites is drained, or after 5 hours. We will monitor blood glucose levels during infusions using a continuous glucose monitor.


Locations(1)

Jennifer Rauw

Victoria, British Columbia, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05025878


Related Trials